Endocrine-related injuries associated with immune checkpoint inhibitors: what endocrinologists and oncologists should know / 中华内分泌代谢杂志

ABSTRACT

The development of medications known as immune checkpoint inhibitors(ICPis) has been a milestone of cancer therapy. However, the increasing use of ICPis in recent years has caused a diverse spectrum of immune-related adverse events, including endocrine glands injury. ICPis-induced endocrinopathies are new challenges brought by advances of medicine as well as become the hot topics in both endocrinology and oncology. It is important that endocrinologists and oncologists should know how to perform proper assessment and clinical management once ICPis-induced endocrinopathies occur. Interdisciplinary collaboration is required to deal with this medical problem in order to improve overall survival and quality of life for patients with various cancer.